Trial Profile
A phase 1 study of combination therapy with gemcitabine S-1 and leucovorin in patients with pancreatic cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2015
Price :
$35
*
At a glance
- Drugs Folinic acid (Primary) ; Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms GSL-1
- 01 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 27 Mar 2012 New trial record